188 related articles for article (PubMed ID: 20664591)
1. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.
Garrido-Laguna I; Tan AC; Uson M; Angenendt M; Ma WW; Villaroel MC; Zhao M; Rajeshkumar NV; Jimeno A; Donehower R; Iacobuzio-Donahue C; Barrett M; Rudek MA; Rubio-Viqueira B; Laheru D; Hidalgo M
Br J Cancer; 2010 Aug; 103(5):649-55. PubMed ID: 20664591
[TBL] [Abstract][Full Text] [Related]
2. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
Ma WW; Jacene H; Song D; Vilardell F; Messersmith WA; Laheru D; Wahl R; Endres C; Jimeno A; Pomper MG; Hidalgo M
J Clin Oncol; 2009 Jun; 27(16):2697-704. PubMed ID: 19380450
[TBL] [Abstract][Full Text] [Related]
3. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
4. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.
Chiu CW; Nozawa H; Hanahan D
J Clin Oncol; 2010 Oct; 28(29):4425-33. PubMed ID: 20823411
[TBL] [Abstract][Full Text] [Related]
5. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
[TBL] [Abstract][Full Text] [Related]
6. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.
Armstrong AJ; Netto GJ; Rudek MA; Halabi S; Wood DP; Creel PA; Mundy K; Davis SL; Wang T; Albadine R; Schultz L; Partin AW; Jimeno A; Fedor H; Febbo PG; George DJ; Gurganus R; De Marzo AM; Carducci MA
Clin Cancer Res; 2010 Jun; 16(11):3057-66. PubMed ID: 20501622
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N
Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.
Sabine VS; Sims AH; Macaskill EJ; Renshaw L; Thomas JS; Dixon JM; Bartlett JM
Breast Cancer Res Treat; 2010 Jul; 122(2):419-28. PubMed ID: 20480226
[TBL] [Abstract][Full Text] [Related]
9. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.
Wolpin BM; Hezel AF; Abrams T; Blaszkowsky LS; Meyerhardt JA; Chan JA; Enzinger PC; Allen B; Clark JW; Ryan DP; Fuchs CS
J Clin Oncol; 2009 Jan; 27(2):193-8. PubMed ID: 19047305
[TBL] [Abstract][Full Text] [Related]
10. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma.
Huynh H
Cancer; 2010 Mar; 116(5):1315-25. PubMed ID: 20101735
[TBL] [Abstract][Full Text] [Related]
11. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models.
Chang Q; Chen E; Hedley DW
Cancer Biol Ther; 2009 Oct; 8(20):1893-901. PubMed ID: 20009539
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.
Schmid K; Bago-Horvath Z; Berger W; Haitel A; Cejka D; Werzowa J; Filipits M; Herberger B; Hayden H; Sieghart W
Br J Cancer; 2010 Aug; 103(5):622-8. PubMed ID: 20683448
[TBL] [Abstract][Full Text] [Related]
13. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination.
Carr RM; Duma N; McCleary-Wheeler AL; Almada LL; Marks DL; Graham RP; Smyrk TC; Lowe V; Borad MJ; Kim G; Johnson GB; Allred JB; Yin J; Lim VS; Bekaii-Saab T; Ma WW; Erlichman C; Adjei AA; Fernandez-Zapico ME
Pancreatology; 2020 Sep; 20(6):1115-1122. PubMed ID: 32778368
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
[TBL] [Abstract][Full Text] [Related]
15. A combined, rational approach towards inhibition of the MEK-ERK and mTOR pathways in pancreatic ductal adenocarcinoma: promise or deja vu?
Rhim AD
Cancer Biol Ther; 2009 Oct; 8(20):1902-3. PubMed ID: 19783905
[No Abstract] [Full Text] [Related]
16. Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells.
Xu Z; Zhang Y; Jiang J; Yang Y; Shi R; Hao B; Zhang Z; Huang Z; Kim JW; Zhang G
BMC Cancer; 2010 Apr; 10():161. PubMed ID: 20423485
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
[TBL] [Abstract][Full Text] [Related]
18. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics.
Dai B; Kong YY; Ye DW; Ma CG; Zhou X; Yao XD
BJU Int; 2009 Oct; 104(7):1009-16. PubMed ID: 19389013
[TBL] [Abstract][Full Text] [Related]
19. A study on the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through PI3K/AKT/mTOR signaling pathway.
Li B; Yang J; Lu Z; Liu B; Liu F
J BUON; 2019; 24(2):739-745. PubMed ID: 31128031
[TBL] [Abstract][Full Text] [Related]
20. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.
Ma BB; Lui VW; Hui EP; Lau CP; Ho K; Ng MH; Cheng SH; Tsao SW; Chan AT
Invest New Drugs; 2010 Aug; 28(4):413-20. PubMed ID: 19471857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
